[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643117":3},{"organization":4,"armGroups":7,"interventions":55,"overallOfficials":12,"centralContacts":70,"locations":76,"responsibleParty":95,"collaborators":12,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":12,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":126,"whyStopped":12,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Tibet Autonomous Region People's Hospital","OTHER",[8,13,16,19,22,25,28,31,34,37,44,49,52],{"label":9,"type":10,"description":11,"interventionNames":12},"HAPE： Calcium Channel Blocker (CCB) Group","NO_INTERVENTION","Calcium Channel Blocker (CCB) Group: Nifedipine sustained-release tablets: 30-60 mg\u002Fday, orally in 2-3 divided doses;",null,{"label":14,"type":10,"description":15,"interventionNames":12},"HAPE：Glucocorticoid Group","Dexamethasone: 8-16 mg\u002Fday, intravenous injection, tapering off after 3-5 days; Methylprednisolone: 40-80 mg\u002Fday, intravenous injection; Prednisone: 40-60 mg\u002Fday, oral administration;",{"label":17,"type":10,"description":18,"interventionNames":12},"HAPE：Diuretic Group","Furosemide: 40-80 mg\u002Fday, administered intravenously or orally; Spironolactone: 40-80 mg\u002Fday, administered orally; Note: Strictly monitor electrolytes and renal function.",{"label":20,"type":10,"description":21,"interventionNames":12},"HAPE：Theophylline Drugs Group","Aminophylline: 0.25-0.5g, intravenous drip, 1-2 times a day; Doxofylline: 200mg, intravenous drip, 2 times a day;",{"label":23,"type":10,"description":24,"interventionNames":12},"HAPE：Combined Treatment Group","CCB + Glucocorticoid: Nifedipine + Dexamethasone; Glucocorticoid + Diuretic: Dexamethasone + Furosemide; Triple Therapy: CCB + Glucocorticoid + Diuretic.",{"label":26,"type":10,"description":27,"interventionNames":12},"HACE：Osmotic Diuretic Group","0.5-1.0 g\u002Fkg, rapid intravenous infusion, once every 6-8 hours; Hypertonic saline: 3% sodium chloride solution, 250 ml intravenous infusion. Monitoring indicators: intracranial pressure, blood osmotic pressure, renal function.",{"label":29,"type":10,"description":30,"interventionNames":12},"HACE：Intensive Glucocorticoid Treatment Group","High-dose dexamethasone: 16-32 mg\u002Fday, intravenously; Methylprednisolone pulse therapy: 500-1000 mg\u002Fday for 3 days, followed by dosage tapering. Treatment course: 7-10 days with gradual dose reduction.",{"label":32,"type":10,"description":33,"interventionNames":12},"HACE：Combined Intracranial Pressure-Reducing Treatment Group","Mannitol + Glucocorticoid: Mannitol 0.5 g\u002Fkg + Dexamethasone 16 mg\u002Fday; Hypertonic saline + Glucocorticoid: 3% NaCl + Methylprednisolone; Triple therapy: Mannitol + Glucocorticoid + Diuretic.",{"label":35,"type":10,"description":36,"interventionNames":12},"HACE：Other Adjuvant Drug Group","Furosemide: 20-40 mg\u002Fday to reduce cerebral edema; Albumin: 25% albumin 50 ml to increase plasma colloid osmotic pressure; Sodium aescinate: 20-40 mg\u002Fday to improve vascular permeability.",{"label":38,"type":39,"description":40,"interventionNames":41},"Multicenter Study of HAPE：Traditional Classic Treatment Group","EXPERIMENTAL","Oxygen inhalation plus CCB or aminophylline",[42,43],"Device: Multicenter study of HAPE：CPAP or BiPAP Group","Drug: Multicenter study of HAPE group：NO Group",{"label":45,"type":39,"description":46,"interventionNames":47},"Protocol for Proteomics and Peptidomics Study of HAPE：Control Group","40 healthy individuals who are either migrant residents or indigenous residents at high altitude. Age, gender, and residential altitude were strictly matched. Peripheral venous blood samples were collected during the same period.",[48],"Other: Protocol for Proteomics and Peptidomics Study of HAPE：Case Group",{"label":50,"type":10,"description":51,"interventionNames":12},"HAPE Database","To establish a High-Altitude Pulmonary Edema (HAPE) Database (≥1000 cases) through a multicenter retrospective study.",{"label":53,"type":10,"description":54,"interventionNames":12},"HACE Database","To establish a High-Altitude Pulmonary Edema (HACE) Database (≥400 cases) through a multicenter retrospective study.",[56,61,66],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":12},"DEVICE","Multicenter study of HAPE：CPAP or BiPAP Group","Traditional treatment plus CPAP or BiPAP",[38],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":12},"DRUG","Multicenter study of HAPE group：NO Group","Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)",[38],{"type":6,"name":67,"description":68,"armGroupLabels":69,"otherNames":12},"Protocol for Proteomics and Peptidomics Study of HAPE：Case Group","40 patients clinically diagnosed with HAPE. Peripheral venous blood samples were collected during the acute onset stage and prior to any effective intervention.",[45],[71],{"name":72,"role":73,"phone":74,"phoneExt":12,"email":75},"Gesang Luobu, MD","CONTACT","8618108912487","kelsangnorbu@hotmail.com",[77],{"facility":78,"status":12,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Xizang Autonomous Region People's Hospital","Lhasa","Tibet","850000","China","CN",{"type":85,"coordinates":86},"Point",[87,88],91.1,29.65,{"lat":88,"lon":87},[91],{"name":92,"role":73,"phone":93,"phoneExt":12,"email":94},"li hui Yang","13638992795","1640794768@qq.com",{"type":96,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Gesang Lobb","First-Class Chief Physician, Department of Cardiovascular Medicine","100643117","key-diagnostic--therapeutic-technologies-for-severe-acute-high-altitude-disease-sahad-integration-and-application-100643117",false,"NCT07639931","Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and Application","Integration and Application Demonstration of Key Diagnosis and Treatment Technologies for Severe Acute High Altitude Disease","SAHAD","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for severe acute mountain sickness (including high-altitude pulmonary edema \\[HAPE\\] and high-altitude cerebral edema \\[HACE\\]).\n2. Aged 18 to 75 years.\n3. Rapid ascent to an altitude above 2500 m within 72 hours prior to onset.\n\nExclusion Criteria:\n\n1. History of severe cardiopulmonary diseases.\n2. Pregnant women, patients with psychiatric disorders, inability to cooperate with treatment or follow-up, and patients with an expected survival of less than 6 months.\n3. Patients with malignant tumors, severe hepatic or renal insufficiency, or immune system diseases requiring immunosuppressive therapy.",true,"ALL","18 Years","75 Years",{"count":112,"type":113},3035,"ESTIMATED","INTERVENTIONAL",[116],"NA","This study aims to establish a key technical system for the diagnosis and treatment of severe acute mountain sickness based on real-world clinical data in Xizang, develop standardized diagnosis and treatment protocols and an intelligent early warning model, validate its efficacy through multicenter studies, and innovate diagnostic and therapeutic technologies. It will achieve early identification, precise diagnosis, standardized treatment, and intelligent warning of severe acute mountain sickness, comprehensively improving its prevention, control and treatment success rate.",[119,120],"Severe High Altitude Pulmonary Edema","Severe High Altitude Cerebral Edema",[122,123,124,125],"High altitude","Key Diagnostic","Therapeutic Technologies","Severe Acute High Altitude Disease (SAHAD)","NOT_YET_RECRUITING","2026-06-07",{"date":129,"type":130},"2026-06-10","ACTUAL",{"date":132,"type":113},"2026-07-01",{"date":134,"type":113},"2028-12-31",{"name":5,"class":6},1]